When will Anagrelide be available in China?

Anagrelide (Anagrelide) is an antiplatelet drug used to treat adult patients with idiopathic Thrombocytopenic Purpura (Idiopathic Thrombocytopenic Purpura, ITP). ITP is an immune-mediated thrombocytopenic bleeding disorder characterized by an elevated peripheral blood platelet count, resulting in bleeding tendencies.

Anagrelide is not yet on the market in China, so patients cannot purchase it domestically and need to purchase the drug through overseas channels. Anagrelide only has the original drug. Outside the mainland, there is the Hong Kong version of the original drug and the foreign Turkish original drug. The price is around 1280 yuan.

Anagrelide exerts its therapeutic effects by regulating the production and breakdown of platelets. It mainly reduces the production of platelets by inhibiting the differentiation and maturation of megakaryocytes. In addition, anagrelide can promote the breakdown and clearance of platelets, thereby reducing the number of platelets.

Specifically, anagrelide inhibits the activity of phosphoribose isomerase (PRIs), thereby reducing the differentiation and maturation of megakaryocytes, thereby reducing platelet production. In addition, anagrelide can also block the platelet production factor (PDGF) signaling pathway, further inhibiting platelet production.

Anagrelide is often considered as a second-line treatment option after failure or intolerance of first-line therapy. Dosage is adjusted based on the patient's specific condition and physician's recommendations. Common side effects include cardiovascular side effects (such as tachycardia, arrhythmia), digestive system side effects (such as nausea, vomiting, abdominal pain), nervous system side effects (such as headache, dizziness, fatigue), and blood system side effects (such as anemia, leukopenia), etc.